Market Place
Sourcing Support
DifGen Pharma, Aveva Lead U.S. PASC Immune Therapy Collaboration
25 Mar 2026 //
PR NEWSWIRE
FDA Approves DifGen`s Generic Mesalamine ER (250mg/500mg)
11 Mar 2026 //
PR NEWSWIRE
Difgen Pharms’ Generics Mesalamine Receives Approval in US
10 Mar 2026 //
FDA
Difgen Pharma Secures FDA Approval for Fluorometholone Eye Drops
13 Feb 2026 //
PR NEWSWIRE
Difgen Pharms’ Generics Fluorometholone Receives Approval in US
12 Feb 2026 //
FDA
DifGen Acquires FDA-Registered Finished Dosage Manufacturing Facility in Florida
18 Mar 2024 //
PR NEWSWIRE
DifGen Pharmaceuticals Successfully Launches A Second Product - Buprenorphine
02 Nov 2023 //
PR NEWSWIRE
DifGen Completes USFDA Audit of Manufacturing Site Aveva Drug Delivery Systems
06 Sep 2023 //
PR NEWSWIRE
DifGen Pharmaceuticals Acquires Aveva Drug Delivery Services Inc
24 Apr 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.